To see all protocols that comply with the WHO Essential Medicine List 
  1. Home
  2. Cancer genetics
  3. Adult
  4. Risk management

VHL (von Hippel-Lindau) disease – risk management

On this page
Expand all Collapse all Back to top

Von Hippel-Lindau (VHL) disease is an autosomal dominant predisposition to renal clear cell carcinoma, phaeochromocytoma, retinal haemangioblastomas (commonly known as retinal angiomas) and central nervous system haemangioblastomas. Approximately 20% of people with VHL have VHL as a result of a de novo pathogenic variant.r Genetic anticipation has been reported in families with VHL.r

This risk management guideline has been developed for individuals who have NOT been diagnosed with a relevant cancer/tumour. The care of affected individuals should be individualised based on their clinical situation, and the monitoring they need as part of their treatment and post-treatment follow-up. 

The risk management of an individual with a pathogenic variant in two or more genes that confer a predisposition to cancer should also be individualised.

Exclusion criteria

  • A first degree (blood) relative of an individual with a clinical diagnosis of VHL but no pathogenic variant 
Cancer/tumour  Risk for this group by age 70 Mean age (years) General population to age 70
Retinal angioma  Up to 92%* 25 Unable to obtain
Cerebellar haemangioblastoma Up to 85%* 30 Unable to obtain
Renal cell carcinoma Up to 80%* 40 (+/-10 yrs) 0.8% (all kidney cancer)**
Epididymal cystadenoma Up to 54% of malesr Unable to obtain Unable to obtain
Spinal haemangioblastoma  Up to 50%* 33 Unable to obtain
Phaeochromocytoma  Up to 30%* 24  Unable to obtain
Pancreatic neuroendocrine tumour 12%r 35 Unable to obtain
Endolymphatic sac tumour Up to 4%r 30 Unable to obtain

* Based on the 2007 review of 573 VHL patients by Ong et al.r These figures are likely to be an overestimate of risk as no adjustment was made for proband ascertainment

** Source: Australian Institute of Health and Welfare (AIHW) 2021 Cancer Data in Australia; Canberra: AIHW. <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancer-risk-data-visualisation>. (2017 data)

The choice of risk management strategy should take into account current age, other health issues and residual cancer risk.

Cancer/tumour type Recommendationsr
    Age

Strategy and frequency
Renal cell carcinoma Surveillance From age 10 years Abdominal MRI 2nd yearly with abdominal ultrasound in intervening years
Pancreatic neuroendocrine tumours Surveillance From age 10 years Abdominal MRI 2nd yearly with abdominal ultrasound in intervening years
Phaeochromocytoma Surveillance From age 2 years
  • Annual physical examination with BP
  • Annual fasting free plasma metanephrines and if available plasma 3-methoxytyramine (if plasma unavailable 24-hour urine free metanephrines)

Genotype-phenotype correlations (VHL type1, type2A-C) are not yet well enough defined to justify distinct surveillance paradigms.

The utility of nuclear scans for routine screening in the detection of von Hippel-Lindau disease-associated tumours remains unclear.

See also Measurement and tests for biogenic amines including information for patients who are having tests

Tumour type Recommendationsr
    Age Strategy and frequency
Cerebellar and spinal haemangioblastoma Surveillance From age 8 years MRI brain and spine 2nd yearly
Retinal haemangioblastoma Surveillance From age 1 year Paediatric review at birth and annual ophthalmologic review
Endolymphatic sac tumour Surveillance At school entry
  • Baseline audiometry then 2nd-3rd yearly thereafter
  • MRIs performed as above to pay particular attention to the detection of endolymphatic sac tumours
Epididymal cystadenoma Surveillance No routine surveillance required as rarely symptomatic.

Pregnancy

While studies are conflicting, there may be a risk of progression of cerebellar haemangioblastomas during pregnancy. Undiagnosed phaeochromocytoma may pose additional risks during pregnancy, especially during labour and delivery. Consider referral to a specialist high-risk pregnancy unit.

Hearing loss and vestibulopathy

Irreversible hearing loss, tinnitus, vertigo and cranial nerve dysfunction can occur due to endolymphatic sac tumours. The early detection of hearing loss and vestibulopathy and surgical intervention can preserve hearing and ameliorate vestibular symptoms.r

Renal cell carcinoma

Multicentric and bilateral RCCs are common. Where possible, the management of renal cell carcinomas should be undertaken in a unit with expertise in nephron-sparing surgery.

Internationally agreed expert opinion.r

First degree blood relatives (parents/brothers/sisters/children) are at up to 50% risk of having inherited the pathogenic variant. More distant relatives may also be at risk of inheriting the pathogenic variant. Genetic relatives should be referred to a clinical genetics service or familial cancer centre to discuss predictive genetic testing.

Informing family members about hereditary cancer

[%id%]
[%title%]
[%abstract%]

Version 7

Date Summary of changes
21/10/2021

Protocol reviewed at October 2019 cancer genetics reference committee meeting. Discussion continued via email. Approved for publication with the following changes made:

  • Target group: 
    • "syndrome" changed to "disease"
    • "retinal angiomas" changed to "retinal hemangioblastomas (commonly known as retinal angiomas)"
    • Inserted: "Approximately 20% of people with VHL have VHL as a result of a de novo pathogenic variant."
  • Lifetime risk of cancer table:
    • Heading changed to "Lifetime risk of cancer/tumour"
    • Risk for general population updated to include AIHW 2017 data
    • Pancreatic neuroendocrine tumour: Risk for this group by age 70: figure changed from "10-17%" to "12%" 
  • Cancer risk management guidelines:
    • Heading changed to "Cancer/tumour risk management guidelines"
    • Sentence added above table: "The choice of risk management strategy should take current age, other health issues and residual cancer risk into account." 
    • Table:
      • Row 1: "and pancreatic neuroendocrine tumour"  deleted
      • Row 2: "Pancreatic neuroendocrine tumour" inserted
      • Risk-reducing medication rows deleted
    • Inserted after table: "Genotype-phenotype correlations (VHL type1, type2A-C) are not yet well enough defined to justify distinct surveillance paradigms. The utility of nuclear scans for routine screening in the detection of von Hippel-Lindau disease-associated tumours remains unclear."
  • Non-cancer risk management guidelines: Cerebellar and spinal haemangioblastoma:
    • Surveillance starting age changed from age 10 years to age 8 years
    • Risk-reducing medication row deleted
  • Management of associated health problems: Renal cell carcinoma: Inserted: "Multicentric and bilateral RCCs are common."
  • Support and information: template wording updated
  • Website resources updated
  • "Mutation" changed to "pathogenic variant" throughout document for consistency among eviQ cancer genetics protocols per agreement among the cancer genetics reference committees' chairs. Definition of "pathogenic variant" added as a pop-up.

Version number increased to V.7. Review in two years.

Version 6

Date Summary of changes
20/12/2010 Approved.
06/05/2013

Discussed at August 20, 2012, meeting, review continued via email and the following changes made:

  • Opening paragraph updated.
  • Target group - point 3 family changed to individual.
  • Lifetime risk of cancer - heading changed to lifetime risk of tumour and table updated.
  • Cancer risk management guidelines - table updated.
  • Non-cancer risk management guidelines table - added.
  • Management of associated health problems and side effects - pregnancy section updated, hearing loss and vestibulopathy section added.
  • Reference list reviewed and updated.
14/04/2016 Sentence added to Risk Management template: "This risk management guideline has been developed for individuals who have NOT been diagnosed with a relevant cancer/tumour.  The care of affected individuals should be individualised based on their clinical situation, and the monitoring they need as part of their treatment and post-treatment follow up". 
31/05/2017 Transferred to new eviQ website. Version number changed to V.3.
 

 Further references used to develop this protocol:

Manski, T. J., D. K. Heffner, G. M. Glenn, et al. 1997. "Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease." JAMA 277(18):1461-1466.

Zanotelli, D. B., E. Bruder, E. Wight, et al. 2010. "Bilateral papillary cystadenoma of the mesosalpinx: a rare manifestation of Von Hippel-Lindau disease." Arch Gynecol Obstet 282(3):343-346. 
14/09/2018

Discussed at May 24, 2018 meeting, review continued via email and the following changes made:

  • Summary - description of VHL updated and sentence re genetic anticipation reported in families with VHL added. Sentence regarding the guideline has been developed for individuals who do NOT have a relevant cancer/tumour removed.
  • Lifetime risk of cancer table – title changed to ‘tumour/cancer’ and tumour/ancer types and figures updated
  • Recommendations – cancers/tumours separated into cancer and non-cancer recommendation tables – recommendations updated as per new evidence/references
    • Phaeochromocytoma recommendations to be made consistent with SDH guidelines
    • Endolymphatic sac tumours – add comment re MRI brain screening to pay particular attention to endolytic sac tumours
  • Management of associated health problems – updated and RCC comment added
  • References updated
  • Version updated to 4
28/08/2019 Protocol title changed from 'Risk management for von Hippel-Lindau (VHL)' to 'VHL (von Hippel-Lindau disease) – risk management' in accordance with Cancer Genetics Reference Committees' consensus. Version number increased to V.5.
3/10/2019 "Mutation" changed to "pathogenic variant" throughout document for consistency among eviQ cancer genetics protocols per agreement among the cancer genetics reference committees' chairs. Definition of "pathogenic variant" added as a pop-up. Version number increased to V.6.

The information contained in this document is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to care or treatment. Any clinician seeking to apply or consult this document is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/397

10 Aug 2022